Roivant Sciences Ltd. (ROIV)
| Market Cap | 1.34B |
| Revenue (ttm) | 29.95M |
| Net Income (ttm) | n/a |
| Shares Out | 222.08M |
| EPS (ttm) | -4.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 300,945 |
| Open | 6.24 |
| Previous Close | 6.11 |
| Day's Range | 6.01 - 6.28 |
| 52-Week Range | 5.80 - 9.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Financial Performance
Financial StatementsNews
Roivant Provides Corporate Updates
NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health,...
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Montes Archimedes Acquisition Corp. - MAAC
NEW YORK, May 21, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action...
2 Best Biotech Stocks to Buy Now
Here's how a drug discovery company and a coronavirus vaccine drugmaker can boost investors' portfolios.
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning. The SPAC Deal: Roviant Sciences announ...
Montes Archimedes Acquisition Corp. Announces the Separate Trading of its Shares of Class A Common Stock and Warrants...
MENLO PARK, Calif., Nov. 25, 2020 /PRNewswire/ -- Montes Archimedes Acquisition Corp. (Nasdaq: MAACU) (the "Company") announced that, commencing November 27, 2020, holders of the units sold in the Compa...
Montes Archimedes Acquisition Corp Announces Pricing of $400,000,000 Initial Public Offering
MENLO PARK, Calif., Oct. 6, 2020 /PRNewswire/ -- Montes Archimedes Acquisition Corp (the "Company" or "Montes Archimedes"), a special purpose acquisition company formed for the purpose of entering into ...